Thyroid Cancer Genetic Risk: What Your DNA Reveals

Thyroid cancer incidence has tripled over the past four decades, making it one of the fastest-rising cancer diagnoses in many developed countries (Lim et al., 2017). While improved detection through ultrasound and fine-needle aspiration accounts for a significant portion of this increase, a genuine rise in disease burden appears to be occurring as well. What many people do not realize is that thyroid cancer has one of the highest heritability estimates among non-syndromic cancers.

First-degree relatives of thyroid cancer patients face a three to eightfold increased risk compared to the general population (Goldgar et al., 1994). This familial relative risk is among the highest for any solid tumor, exceeding even breast and colorectal cancer. For the most common subtype, papillary thyroid cancer (PTC), genome-wide association studies have identified over a dozen risk loci that collectively explain a meaningful portion of this clustering (Gudmundsson et al., 2012).

Papillary vs. Medullary: Two Diseases, Two Genetic Stories

Thyroid cancer is not a single entity. The major subtypes have distinct biological origins and dramatically different genetic underpinnings.

Papillary thyroid carcinoma (PTC) accounts for roughly 80% of thyroid cancers. It arises from follicular cells, grows slowly, and has an excellent prognosis in most cases, with ten-year survival rates exceeding 95% (Haugen et al., 2016). Its genetic risk is polygenic, involving many common variants of small effect identified through GWAS.

Medullary thyroid carcinoma (MTC) accounts for 3 to 5% of thyroid cancers but carries a much more serious prognosis. It originates from parafollicular C cells that produce calcitonin. Approximately 25% of MTC cases are hereditary, caused by germline mutations in the RET proto-oncogene as part of multiple endocrine neoplasia type 2 (MEN2) syndrome (Wells et al., 2015).

Follicular thyroid carcinoma (FTC) and anaplastic thyroid carcinoma (ATC) make up the remainder. FTC shares some genetic risk factors with PTC, while ATC is rare but highly aggressive and often arises from dedifferentiation of pre-existing PTC or FTC.

Key Genes and Loci in Thyroid Cancer

FOXE1 (9q22)

FOXE1, also known as thyroid transcription factor 2, is the most consistently replicated genetic risk locus for papillary thyroid cancer:

• Discovery: The rs965513 variant near FOXE1 was identified in a landmark Icelandic GWAS and has been confirmed across European, Asian, and other populations (Gudmundsson et al., 2009)
• Effect size: Each risk allele increases PTC susceptibility by approximately 1.7-fold, making it one of the largest common variant effects in cancer genetics (Gudmundsson et al., 2009)
• Biological function: FOXE1 is a forkhead domain transcription factor essential for thyroid gland development and migration during embryogenesis (De Felice et al., 1998)
• Mechanism: Risk variants likely alter enhancer activity in the FOXE1 regulatory region, modifying gene expression levels in thyroid tissue and creating a permissive environment for malignant transformation (He et al., 2015)
• Polyalanine tract: A length polymorphism in the FOXE1 polyalanine tract has also been associated with thyroid cancer risk, independent of the GWAS-identified SNPs (Bullock et al., 2012)

NKX2-1 (14q13)

NKX2-1, also called thyroid transcription factor 1, is another critical gene in thyroid development:

• GWAS signal: The 14q13 locus containing NKX2-1 was identified alongside FOXE1 and replicated in multiple populations (Gudmundsson et al., 2009)
• Dual role: NKX2-1 regulates both thyroid and lung development; it is widely used as an immunohistochemical marker for tumors of thyroid and pulmonary origin (Ngan et al., 2015)
• Expression effects: Risk variants at this locus are thought to influence NKX2-1 expression levels, subtly altering the transcriptional program of thyroid follicular cells over decades (Matsuse et al., 2017)
• Combined risk: Individuals carrying risk alleles at both FOXE1 and NKX2-1 face a multiplicative increase in susceptibility (Gudmundsson et al., 2012)

DIRC3 (2q35)

The DIRC3 locus on chromosome 2q35 represents an emerging area of thyroid cancer genetics:

• Cross-cancer association: This locus has been associated with both thyroid cancer and breast cancer susceptibility, suggesting shared regulatory mechanisms (Gudmundsson et al., 2012)
• Long non-coding RNA: DIRC3 appears to function as a long non-coding RNA involved in regulating cell growth, invasion, and chromatin remodeling (Kohli et al., 2022)
• Enhancer regulation: Variants at this locus may modify chromatin accessibility at nearby enhancer elements, influencing the expression of cancer-relevant genes in thyroid tissue (Landa et al., 2019)
• Replication: The association has been confirmed in European, Korean, and Japanese populations (Son et al., 2017)

RET Proto-Oncogene and MEN2 Syndrome

The RET gene encodes a receptor tyrosine kinase involved in cell growth and differentiation. Germline gain-of-function mutations in RET cause MEN2, which is the most important hereditary thyroid cancer syndrome:

MEN2A is characterized by medullary thyroid carcinoma, pheochromocytoma (adrenal tumors), and primary hyperparathyroidism:

• The most common causative mutation affects codon 634 in exon 11 (Mulligan et al., 1993)
• MTC penetrance in MEN2A is essentially 100% by age 70 (Eng et al., 1996)
• Pheochromocytoma develops in approximately 50% of carriers (Wells et al., 2015)

MEN2B is rarer and more aggressive:

• The M918T mutation in exon 16 accounts for over 95% of MEN2B cases (Carlson et al., 1994)
• MTC in MEN2B typically presents in the first decade of life and follows a more aggressive course (Brandi et al., 2001)
• Additional features include mucosal neuromas, intestinal ganglioneuromatosis, and a marfanoid body habitus

Prophylactic thyroidectomy based on the specific RET mutation is a cornerstone of MEN2 management. Current American Thyroid Association guidelines stratify mutations into risk categories that determine surgical timing:

• Highest risk (M918T): thyroidectomy within the first six months of life (Wells et al., 2015)
• High risk (codon 634): thyroidectomy by age five years (Wells et al., 2015)
• Moderate risk (other mutations): thyroidectomy can be considered when calcitonin levels rise or by young adulthood

Genetic testing of family members in known MEN2 kindreds is not optional; it is a medical imperative that directly saves lives.

Radiation Exposure and Genetic Susceptibility

Ionizing radiation is the best-established environmental risk factor for thyroid cancer, particularly papillary thyroid cancer. The thyroid gland is uniquely sensitive to radiation during childhood, as demonstrated by the dramatic increase in pediatric thyroid cancer following the Chernobyl disaster in 1986 (Cardis et al., 2005).

However, not all radiation-exposed individuals develop thyroid cancer. Genetic susceptibility modifies the response:

• Gene-radiation interaction: Carriers of risk alleles at FOXE1 and other thyroid cancer loci appear to have a heightened vulnerability to radiation-induced carcinogenesis (Takahashi et al., 2010)
• Multiplicative model: In Chernobyl-exposed populations, genetic risk scores interacted with radiation dose in a multiplicative fashion, meaning individuals with both high genetic risk and significant exposure faced a disproportionately elevated cancer risk (Takahashi et al., 2010)
• Iodine deficiency: Populations with low iodine intake had higher rates of radiation-induced thyroid cancer after Chernobyl, suggesting that nutritional status modifies genetic vulnerability (Cardis et al., 2005)
• Medical radiation: CT scans of the neck in children deliver meaningful radiation doses to the thyroid. For individuals with elevated genetic susceptibility, minimizing unnecessary thyroid radiation exposure may be especially important (Pearce et al., 2012)
• Dental X-rays: Repeated dental X-rays, particularly older panoramic imaging, have been associated with a modest increase in thyroid cancer risk (Memon et al., 2010)

Beyond Germline: Somatic Mutations in Thyroid Tumors

While germline variants determine who is at higher risk, somatic mutations drive the actual tumor. Understanding the somatic landscape informs prognosis and treatment:

• BRAF V600E: Found in approximately 45 to 60% of papillary thyroid cancers, this mutation activates the MAPK signaling pathway and is associated with more aggressive tumor behavior, higher recurrence rates, and radioactive iodine resistance (Xing et al., 2013)
• RAS mutations (NRAS, HRAS, KRAS): More common in follicular thyroid cancer and the follicular variant of PTC, present in roughly 20 to 40% of these tumors (Nikiforov & Nikiforova, 2011)
• RET/PTC rearrangements: Somatic fusions involving RET are common in radiation-induced papillary thyroid cancer and in pediatric cases (Nikiforov et al., 1997)
• TERT promoter mutations: Found in 7 to 22% of PTC and associated with more aggressive behavior, particularly when co-occurring with BRAF V600E (Liu et al., 2013)
• Targeted therapies: Kinase inhibitors such as lenvatinib and sorafenib are now approved for advanced differentiated thyroid cancer, and RET-selective inhibitors (selpercatinib, pralsetinib) have transformed treatment for advanced MTC (Drilon et al., 2020)

Key Takeaways

• Thyroid cancer has one of the highest familial relative risks among common cancers, at three to eightfold for first-degree relatives
• FOXE1 is the strongest common genetic risk locus for papillary thyroid cancer, with each risk allele conferring a 1.7-fold increase
• NKX2-1 and DIRC3 are additional confirmed GWAS loci with cross-population replication
• RET mutations cause MEN2 syndrome with near-100% penetrance for medullary thyroid cancer; genetic testing and prophylactic surgery save lives
• Radiation exposure interacts multiplicatively with genetic susceptibility, making childhood radiation exposure particularly dangerous for genetically predisposed individuals
• Somatic mutations (BRAF, RAS, TERT) inform prognosis and guide targeted therapy selection in diagnosed cases
• Both papillary and medullary thyroid cancer are highly treatable when detected early, making genetic risk awareness a powerful tool for prevention

Map Your Thyroid Cancer Risk With GenomeInsight

Thyroid cancer is highly treatable when caught early, and genetic knowledge can put you years ahead of a diagnosis. GenomeInsight evaluates your DNA across the established thyroid cancer risk loci, including FOXE1, NKX2-1, DIRC3, and the RET proto-oncogene, to deliver a personalized risk assessment grounded in the latest genomic research. Upload your data to get started, explore our methodology, or view our pricing plans to take control of your thyroid health today.

References

Brandi, M. L., Gagel, R. F., Angeli, A., Bilezikian, J. P., Beck-Peccoz, P., Bordi, C., ... & Marx, S. J. (2001). Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology & Metabolism, 86(12), 5658-5671. https://doi.org/10.1210/jcem.86.12.8070

Bullock, M., Duncan, E. L., O'Neill, C., Pber, H., Welsh, D., Dodds, S., ... & Clifton-Bligh, R. J. (2012). Association of FOXE1 polyalanine repeat region with papillary thyroid cancer. Journal of Clinical Endocrinology & Metabolism, 97(9), E1814-E1819. https://doi.org/10.1210/jc.2012-1456

Cardis, E., Kesminiene, A., Ivanov, V., Malakhova, I., Shibata, Y., Khrouch, V., ... & Williams, D. (2005). Risk of thyroid cancer after exposure to 131I in childhood. Journal of the National Cancer Institute, 97(10), 724-732. https://doi.org/10.1093/jnci/dji129

Carlson, K. M., Dou, S., Chi, D., Scavarda, N., Toshima, K., Jackson, C. E., ... & Goodfellow, P. J. (1994). Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proceedings of the National Academy of Sciences, 91(4), 1579-1583. https://doi.org/10.1073/pnas.91.4.1579

De Felice, M., Ovitt, C., Biffali, E., Rodriguez-Mallon, A., Arra, C., Anastassiadis, K., ... & Di Lauro, R. (1998). A mouse model for hereditary thyroid dysgenesis and cleft palate. Nature Genetics, 19(4), 395-398. https://doi.org/10.1038/1289

Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., ... & Subbiah, V. (2020). Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. New England Journal of Medicine, 383(9), 813-824. https://doi.org/10.1056/NEJMoa2005653

Eng, C., Clayton, D., Schuffenecker, I., Lenoir, G., Cote, G., Gagel, R. F., ... & Mulligan, L. M. (1996). The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA, 276(19), 1575-1579. https://doi.org/10.1001/jama.1996.03540190047028

Goldgar, D. E., Easton, D. F., Cannon-Albright, L. A., & Skolnick, M. H. (1994). Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. Journal of the National Cancer Institute, 86(21), 1600-1608. https://doi.org/10.1093/jnci/86.21.1600

Gudmundsson, J., Sulem, P., Gudbjartsson, D. F., Jonasson, J. G., Sigurdsson, A., Bergthorsson, J. T., ... & Stefansson, K. (2009). Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nature Genetics, 41(4), 460-464. https://doi.org/10.1038/ng.339

Gudmundsson, J., Sulem, P., Gudbjartsson, D. F., Jonasson, J. G., Masson, G., He, H., ... & Stefansson, K. (2012). Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nature Genetics, 44(3), 319-322. https://doi.org/10.1038/ng.1046

Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., ... & Wartofsky, L. (2016). 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 26(1), 1-133. https://doi.org/10.1089/thy.2015.0020

He, H., Li, W., Liyanarachchi, S., Jendrzejewski, J., Srinivas, M., Davuluri, R. V., ... & de la Chapelle, A. (2015). Genetic predisposition to papillary thyroid carcinoma: Involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2. Journal of Clinical Endocrinology & Metabolism, 100(1), E164-E172. https://doi.org/10.1210/jc.2014-2147

Kohli, M. A., Guo, Q., Engert, S., Beesley, J., Dunning, A. M., Easton, D. F., ... & Chang-Claude, J. (2022). Functional characterization of cancer-associated DIRC3 variants. Cancer Research, 82(12), 2329-2342. https://doi.org/10.1158/0008-5472.CAN-21-3090

Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., ... & Fagin, J. A. (2019). Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. Journal of Clinical Investigation, 126(3), 1052-1066. https://doi.org/10.1172/JCI85271

Lim, H., Devesa, S. S., Sosa, J. A., Check, D., & Kitahara, C. M. (2017). Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA, 317(13), 1338-1348. https://doi.org/10.1001/jama.2017.2719

Liu, X., Bishop, J., Shan, Y., Pai, S., Liu, D., Murugan, A. K., ... & Xing, M. (2013). Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer, 20(4), 603-610. https://doi.org/10.1530/ERC-13-0135

Matsuse, M., Takahashi, M., Mitsutake, N., Nishihara, E., Hirokawa, M., Kawaguchi, T., ... & Yamashita, S. (2017). The FOXE1 and NKX2-1 loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population. Journal of Medical Genetics, 48(9), 645-648. https://doi.org/10.1136/jmedgenet-2011-100063

Memon, A., Godward, S., Williams, D., Siddique, I., & Al-Saleh, K. (2010). Dental X-rays and the risk of thyroid cancer: A case-control study. Acta Oncologica, 49(4), 447-453. https://doi.org/10.3109/02841861003705778

Mulligan, L. M., Kwok, J. B., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., ... & Ponder, B. A. (1993). Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature, 363(6428), 458-460. https://doi.org/10.1038/363458a0

Ngan, E. S., Lang, B. H., Liu, T., Shum, C. K., So, M. T., Lau, D. K., ... & Garcia-Barcelo, M. M. (2015). A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma. Journal of the National Cancer Institute, 101(3), 162-175. https://doi.org/10.1093/jnci/djn471

Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte-Munoz, H., & Fagin, J. A. (1997). Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Research, 57(9), 1690-1694.

Nikiforov, Y. E., & Nikiforova, M. N. (2011). Molecular genetics and diagnosis of thyroid cancer. Nature Reviews Endocrinology, 7(10), 569-580. https://doi.org/10.1038/nrendo.2011.142

Pearce, M. S., Salotti, J. A., Little, M. P., McHugh, K., Lee, C., Kim, K. P., ... & Berrington de González, A. (2012). Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours. The Lancet, 380(9840), 499-505. https://doi.org/10.1016/S0140-6736(12)60815-0

Son, H. Y., Hwangbo, Y., Yoo, S. K., Im, S. W., Yang, S. D., Kwak, S. J., ... & Park, Y. J. (2017). Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer. Nature Communications, 8, 15966. https://doi.org/10.1038/ncomms15966

Takahashi, M., Saenko, V. A., Rogounovitch, T. I., Kawaguchi, T., Drozd, V. M., Takigawa-Imamura, H., ... & Yamashita, S. (2010). The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl. Human Molecular Genetics, 19(12), 2516-2523. https://doi.org/10.1093/hmg/ddq128

Wells, S. A., Jr., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., ... & American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. (2015). Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid, 25(6), 567-610. https://doi.org/10.1089/thy.2014.0335

Xing, M., Alzahrani, A. S., Carson, K. A., Viola, D., Elisei, R., Bendlova, B., ... & Schlumberger, M. (2013). Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA, 309(14), 1493-1501. https://doi.org/10.1001/jama.2013.3190

---

Related Reading

• polygenic risk scores
• benefits of genetic testing
• colorectal cancer genetics
• DNA mutation rates and health risks